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Abstract
The inﬂammatory environment dramatically impacts the formation of cancer at many levels, acting on the stem cell to foster the initia-
tion of cancer all the way through its contribution to metastatic disease. Using Helicobacter-induced gastric cancer as an example,
it can be seen that, early on, chronic inﬂammation exhausts tissue stem cells, forcing the remaining stem cells to work overtime and
calling in replacement cells from marrow sources. Marrow-derived stromal cells orchestrate growth and remodelling through secreted
factors and cell–cell communication. Once cancer is present, the inﬂammatory environment is responsible for the continued growth sig-
nals to the cancer stem cells and to the stromal cells which become a vital part of the cancer niche as well as the pre-metastatic niche
which will effectively lure cancer cells into peripheral organs for distant growth. This understanding of the inﬂammatory environment
and its many effects on cancer throughout its natural history provides intervention targets directed at the unique aspects of cancer
behaviour.
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Introduction
Helicobacter pylori has gone from an unknown organism ‘con-
taminating’ pathology slides to the celebrity of the past cen-
tury. Once passed over, it is now recognized as the leading
cause of gastric cancer worldwide, largely through its effects
on the host immune response. Thus Helicobacter has
become an important tool for the study of inﬂammation-
induced cancers, and has provided for us a glimpse into the
turmoil of chronically infected tissues.
Over the last several years there has been a resurgence of
interest in the association of inﬂammation and cancer. While
inﬂammation was initially felt to be a beneﬁcial response, we
now recognize that in many situations inﬂammation may in
fact drive malignancy. Many cancers, in addition to those
related to Helicobacter, are caused by infections. Infections
induce malignancy through direct effects on tissues or by
induction of a harmful immune response. Our understanding
of cancer initiation and progression has also matured in the
last several years. It is now recognized that a peripherally
located stem cell (rather than a terminally differentiated cell)
is the target of transformation; this cancer stem cell or
tumour-initiating cell is responsible for cancer growth.
Here we will use H. pylori infection to explore the interac-
tion of the inﬂammatory environment with the gastric tissue
from initiation through to metastasis, with an emphasis on
how the gastric stem cell responds to inﬂammation. In order
to do this, we must draw from what has been learned from
inﬂammatory environments in other tissues at risk of inﬂam-
mation-mediated cancers, and combine research and clinical
ﬁndings concerning many solid and liquid tumours. We must
also look to the normal tissue stem cell for clues on how
the cancer stem cell responds to the inﬂammatory environ-
ment. We must infer the effect of inﬂammation on the can-
cer stem cell, which for many types of cancer remains an
elusive player.
Infection as a Cause of Cancer
Epidemiologically, chronic inﬂammatory disorders show a
strong association with cancer risk. Many malignancies are
initiated by tissue injury or chronic inﬂammation, which can
be linked to known bacterial, viral or parasitic infections [1].
Within the gastrointestinal tract, H. pylori infection and
gastric cancer, and chronic viral hepatitis and hepatocellular
carcinoma, are perhaps the most widely recognized. In other
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organ systems the evidence of an association between infec-
tion and cancer is equally strong and includes diseases such
as bladder cancer as a result of schistosomiasis, cervical can-
cer as a result of human papilloma virus and osteosarcoma
as a result of chronic bacterial osteomyelitis (Table 1). Over-
all, it has been estimated that upwards of 15% of malignan-
cies worldwide can be attributed speciﬁcally to chronic
infections. We now recognize that a major factor in these
infections causing cancer is the initiation and perpetuation of
a deleterious immune response; therefore, it is not surprising
that many other cancers are linked to chronic inﬂammation
initiated by agents other than infection.
These include esophageal adenocarcinoma as a result of
gastroesophageal reﬂux, colon cancer as a result of inﬂam-
matory bowel disease, skin cancer arising in scar tissue and
at sites of chronic irritation and lung cancer as a result of
smoking. These examples likely represent the most obvious
cases, and may underestimate the role of inﬂammation in ini-
tiating disease as most cancers do not arise in normal tissue
but require some initial degree of tissue alteration which
may ultimately link these cancers to inﬂammation as well.
Helicobacter as a cause of Gastric Cancer
Helicobacter pylori was rediscovered by Marshall and Warren
in 1984 [2,3], and has been named a class I carcinogen [1].
Helicobacter pylori infection has been recognized as the causa-
tive agent for up to 80% of all cases of gastric adenocarci-
noma and 90–95% of gastric MALT lymphomas. Bacterial
factors are associated with a higher likelihood of gastric
cancer through mechanisms which are multifactorial. The
bacterium contains a number of different virulence factors,
including adherence proteins, urease and the products of the
cag pathogenicity island. There is evidence of direct inter-
action between bacteria and mucosal cells [4,5]. More
virulent bacteria also act through the induction of a stronger
immune reaction from the host; cagA+ strains are associated
with more severe inﬂammation and a greater chance of pro-
gressing to adenocarcinoma (reviewed in [5]) while recent
data point out the possible oncogenic role of CagA [6]. It is
the interaction between H. pylori and the host immune
response which determines the degree of inﬂammation and
the likelihood of progression to cancer. In order to under-
stand the role inﬂammation plays in the initiation and pro-
gression of carcinoma, we must understand the components
of the inﬂammatory environment of Helicobacter and other
chronic infections.
Host Immune Response
Helicobacter pylori’s preferred niche is within the mucous
layer overlying gastric epithelial cells, where a neutral pH is
maintained and the organism is protected from both gastric
contents and the sweeping motility of the gut. Helicobacter
pylori is not invasive and infrequently attaches to the cell sur-
face. How an immune response is initiated is not clear, but
regardless of the initiating event, an early innate immune
response is quickly followed by a vigorous but ineffective
adaptive response. The pattern of this adaptive response
appears to be critical in determining disease outcomes.
The Th1 cytokine response is most closely linked to dis-
ease. Various manipulations within mouse models of infection
clearly distinguish the immune response, and not the bacte-
rial strain or the genetic background of the host, as the driv-
ing force for cancer development [7–11]. With this in mind,
identifying the cytokine proﬁle linked to disease became a
focus of several large studies which identiﬁed interleukin
(IL)-1b, tumor necrosis factor (TNF)-a and IL-10 as key play-
TABLE 1. Infection- and inﬂamma-
tion-associated cancers
Cause Site
Infectious causes
Chronic Helicobacter infection Gastric adenocarcinoma and MALT lymphoma
Chronic pancreatitis Pancreatic cancer
Opisthorchis sinensis infection (liver ﬂuke) Cholangiocarcinoma
Viral hepatitis Hepatocellular carcinoma
Human papilloma virus Anogenital carcinoma
Schistosomiasis Bladder cancer
Pelvic inﬂammatory disease Ovarian cancer
Chronic osteomyelitis Osteosarcoma
Epstein-Barr virus/Malaria Burkett’s lymphoma
Epstein-Barr virus Nasopharyngeal carcinoma
Other environmental causes
Chewing tobacco/oral irritation Oral cancers
Smoking/chronic bronchitis Lung
Asbestos Mesothelioma
Reﬂux disease Barrett’s adenocarcinoma of the esophagus
Ulcerative colitis and Crohn’s disease Colorectal carcinoma
Chronic scar tissue ‘Scar’ cancer arising in the lung, skin and other areas of scarring
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ers in this process, such that high levels of IL-1b and TNF-a,
and low levels of IL-10 confer a 50-fold risk of gastric cancer
[12], further supporting the role of the Th1 response to
infection. How does a Th1 cytokine response lead to dis-
ease? Interferon (IFN)-c, TNF-a and IL1-b have been shown
to increase Fas-mediated apoptosis within several cell types
in the gastric mucosa, leading to cell loss and tissue remodel-
ling [13–15]. There is evidence that Fas signalling may have a
role in proliferation, and in some cases function as an onco-
gene [16]. Tissue loss, cell–cell contact alterations and a
‘healing’ environment all contribute to an environment con-
ducive to cancer formation. In order to understand this rela-
tionship, we ﬁrst must look historically at how inﬂammation
has been viewed, and place the astute observations of our
predecessors in the context of modern experimental data.
The Association of Inﬂammation and Cancer
Virchow was one of the ﬁrst to recognize the association
between inﬂammation and cancer when he noted in 1863 that
cancer arose in areas of chronic inﬂammation (reviewed in
[17]). He speculated that cancer arose from a mature cell
type within the peripheral tissue as a result of, or in spite of,
inﬂammation; the exact mechanism of the association
between inﬂammation and cancer was debated. Also debated
at this time was the identity of the cells giving rise to tumours.
Early arguments came from Cohnheim and Waldeyer. These
two researchers proposed opposing views of the cancer cell
of origin (or tumour-initiating cell) with Cohnheim proposing
that tumours derived from ‘embryonal cell rests’, residual
embryonic cells ‘left behind’ in the adult organism [18].
Waldeyer, on the other hand, proposed that the cancer cell
of origin was a differentiated cell within the epithelial or endo-
thelial compartments. The idea that a peripheral differentiated
cell could become malignant and form a tumour remained a
popular concept for many years. While this concept is still
held by some, recently emerging evidence suggests that a
more primitive cell type is likely responsible for tumours.
Thus tissue progenitor cells and tissue stem cells are emerging
as the likely candidates for the tumour-initiating cell.
As our understanding of the cancer-initiating environment
has undergone a maturation in recent years, so has our con-
cept of tumour structure. We once thought cancer to be a
group of abnormal, poorly regulated cells, each capable of
autonomous growth and with metastatic potential. We now
have a different understanding of tumours, and cancer biolo-
gists are beginning to view tumours, not as a collection of
independently functioning cells, but rather as an organized
hierarchy of cells akin to an organ. Like an organ, there is a
cell or a group of cells which control the growth and survival
of tumours, termed a cancer stem cell.
The concept of a cancer stem cell ﬁnds its origins in the
notion that peripheral organs rely on stem cells for growth
and renewal. These stem cells are a minority of cells, as not
every cell in the organ is capable of division or multiple lines
of differentiation. In the 1950s it was discovered that lethally
irradiated animals could be rescued from bone marrow fail-
ure by reintroduction of whole bone marrow cells from
another compatible animal. The cells responsible for repopu-
lating the bone marrow formed colony units in the spleen,
which could be cultured and therefore identiﬁed. Interest-
ingly, cells which formed colonies could be used to repopu-
late other recipients [19–24] and were found to give rise to
all the formed units of the blood. These ﬁndings veriﬁed that
one cell was capable of giving rise to daughter cells with mul-
tilineage phenotypes and, perhaps more interesting, could be
re-isolated and used to rescue a second or third animal, thus
demonstrating their potential for longevity. Since that time,
the identity of the haematopoietic stem cell has been clearly
deﬁned and the haematopoietic system stands as the refer-
ence standard for stem cell identiﬁcation in other organs.
Based on the concept of an organ-speciﬁc stem cell, and with
the recognition of cancer as a complex multicellular ‘organ-
like’ structure, the concept of a stem cell initiating and prop-
agating cancer emerged.
This idea of a stem cell serving as the tumour-initiating cell
and continuing its role as the cancer stem cell was taken a
step further by Pierce [25] who studied mouse teratocarcino-
mas. His studies were instrumental in forging the notion of
the cancer stem cell as we embrace it today. Individual cancer
cells had the surprising characteristic of forming normal, non-
malignant daughter cells when transplanted into another host.
These individual cells gave rise to daughter cells with varying
degrees of differentiation and function, but were themselves
incapable of propagating a tumour. Recently, a renewed push
to prospectively identify the cancer stem cell in various
tumour types has begun. Several laboratories working on
different tumour types have been able to provide a phenotype
of the cancer stem cells based on surface marker expression.
While there are differences among tumour types, several sim-
ilarities in the surface receptor expression pattern have
emerged, suggesting that we may be close to identifying spe-
ciﬁc properties of cancer stem cells that may be used as ther-
apeutic targets. Isolation of the presumed stem cell
population by ﬂuorescence-activated cell sorting (FACS) or
magnetic bead separation has certainly allowed enrichment
for these elusive cells [26–33]; however, the prospective iden-
tiﬁcation of a single cell capable of recapitulating the original
complex tumour is still not possible for most types of cancer.
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While it is widely accepted that the cancer stem cell
derives from a peripheral tissue stem cell pool, there is acc-
umulating evidence from mouse and human studies that
mobilized pluripotent stem cells originating in the bone mar-
row may seed distant sites of injury and act as the cancer
stem cell [33–39], and may contribute to tumour stroma as
ﬁbroblasts, myoﬁbroblasts and endothelial cells [40–44], and
provide crucial signals to the tumour stem cells.
The pressing questions therefore remain. What is it about
the inﬂammatory environment that encourages the malignant
growth of peripheral organ stem cells? What are the environ-
mental factors which call in circulating pluripotent stem cells,
allowing them to become established within injured tissue?
And ﬁnally, how can we use a model of Helicobacter infection
and gastric cancer to answer these questions? As outlined
previously, initially the presence of inﬂammation at sites of
cancer was interpreted as a defense against a foreign invader.
Leukocyte invasion was seen as ‘attacking’ neoplastic cells and
was therefore viewed as a positive host response. However,
more recent data indicate that, far from a protective role,
inﬂammatory cells can drive initiation and promotion of many
cancers. Cancer has long been viewed as ‘the wound that will
not heal’, and we now recognize this pro-growth environ-
ment as the fan which incites the ﬂame of cancer growth.
What does the Chronic Inﬂammatory
Environment Look Like?
In general, the chronic inﬂammatory environment within any
organ or tissue is composed of cells, matrix, secreted cyto-
kines and chemokines. All of these components contribute
to the environment and pro-cancer signalling. Macrophages,
dendritic cells, lymphocytes and, to a lesser extent, neu-
trophils chronically inﬁltrate tissue and secrete a battery of
inﬂammatory mediators; release enzymes which participate
in tissue remodelling and function to cleave growth factors
to their active forms; and directly release pro-growth fac-
tors, creating an environment similar to that of a wound
healing. The notable difference, however, is that the wound
resulting from chronic inﬂammation does not heal.
A paradox exists. Stem cells are thought to be the source
of all mature adult cells; yet, at the same time, stem cells are
thought to be relatively quiescent. They accomplish their
task by delegating. Stem cells, via asymmetric division, give
rise to two daughter cells. One daughter is a stem cell iden-
tical to the parent, which remains relatively quiescent, and
the other daughter cell, termed the transient amplifying (TA)
cell, is mitotically active and appears to be the powerhouse
of proliferation. It is the TA cell which participates robustly
in the repair process of most tissues. However, as a result
of this rapid proliferation, the TA cell is prone to mutations.
While the TA cells live longer than terminally differentiated
cells, they are not immortal and therefore can be eliminated,
limiting the long-term effects of any mutations they may have
suffered. Once eliminated, though, they need to be replaced
by the tissue stem cell. There is accumulating evidence that,
even in tissues that are thought to be relatively inactive, the
stem cells can be coaxed back into the cell cycle to replenish
the TA population. In doing so, they themselves become vul-
nerable to damage. Therefore, death of normal or injured
cells leads to a compensatory increase in proliferation, ulti-
mately driven by the resident tissue stem cell. While this
increased proliferation heals injury, sustained proliferation
predisposes the stem cell population and the proliferating
cell pool within the tissue to DNA damage. Unlike the TA
cell population which is eliminated periodically, stem cells
are designed to last for the life of the organ. There are two
main outcomes of this scenario. Damage occurring within a
‘wound healing’ environment can be sustained and is cumula-
tive because cells (stem cells and TA cells) bypass many of
the safety checks which normally would remove these cells.
In this situation, damaged cells are allowed to survive and
they avoid elimination by apoptosis, thus placing them at risk
of transformation. Conversely, if the damaged stem cell is
eliminated (discussed later), adjacent stem cells or circulating
stem cells need to take over the stem cell function, or the
tissue risks permanent scarring and dysfunction from inefﬁ-
cient repair and cell renewal.
All inﬂammatory cells have been implicated in the growth
alterations seen in tissue affected by chronic inﬂammation.
Lymphocytes, neutrophils, macrophages and dendritic cells
are found in chronic inﬂammation. Their number and pro-
portions may depend upon the tissue involved, as well as the
stimulus for inﬂammation. Cells within chronically inﬂamed
tissues produce a variety of factors linked to oncogenesis.
Macrophages are a pivotal player in the chronic inﬂammatory
response because of the vast arsenal of bioactive products
they release (Table 2). Lymphocytes, endothelial and epithe-
lial cells also release a storm of biologically active agents
responsible for growth alterations within inﬂamed tissue.
TABLE 2. Factors released by macrophages
Cytokines and chemokines (IL-1, TNF, IL-8)
Growth factors (TGF-b, EGF, FGF, PDGF)
Reactive oxygen species
Nitric oxide
Collagenase
Elastase
Neutral proteases
Enzymes lipase
Coagulation factors
Components of complement
Eicosanoids
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As we have seen in H. pylori clinical research, the quality
(as well as the robustness) of the immune response impacts
disease outcome greatly. Host genetic factors dictate the
individual cytokine and chemokine response to Helicobacter
infection. The cytokine repertoire orchestrates additional
homing of inﬂammatory cells to the area and provides signal-
ling molecules to the epithelium. Several large epidemiologi-
cal studies involving cohorts of gastric cancer patients and
their family members, demonstrate the importance of cyto-
kine polymorphisms. Polymorphisms within cytokine genes
which create a more pro-inﬂammatory environment have
been shown to increase the risk of cancer in the setting of
inﬂammation, but not in the absence of inﬂammation [12,45].
These ﬁndings in gastric cancer have also been shown in
hepatocellular carcinoma arising in the setting of chronic
hepatitis [46,47], stressing that this is not a gastric-speciﬁc
response.
Other cellular components of the inﬂammatory environ-
ment include ﬁbroblasts, myoﬁbroblasts and endothelial cells.
These cells respond to the inﬂammatory environment by
secreting their own repertoire of growth factors, chemokin-
es and matrix modifying factors; by acting to lay down a new
extracellular matrix; and by participating in angiogenesis and
ﬁbrosis.
Architectural distortion interrupts crucial cell–cell signal-
ing, further disrupting the tissue homeostasis. Indeed, inter-
ruptions in cell–cell contact, even in the absence of
inﬂammation, can have dramatic effects on differentiation,
maturation and signalling within the remaining gastric muco-
sal cells [48]. In most tissues, actively proliferating cells
within the transit amplifying population give rise to post
mitotic cells which have a limited life span and are replaced,
thus eliminating them from concern. The transit amplifying
cells themselves are longer lived, but they too are eventually
replaced. It is the stem cell population which is felt to be
continually exposed to the abnormal environment of inﬂam-
mation and bears the brunt of the adverse effects.
To protect themselves, stem cells possess many mecha-
nisms to maintain genomic stability that are not shared by
other cells [49–51]. However, these protective mechanisms
are a double-edged sword. Mechanisms which protect the
stem cell genome also limit the life span of the stem cell
pool and are suggested to contribute to ageing. During
chronic injury and inﬂammation, these processes are greatly
accelerated and the life span of the stem cell appears to be
shortened. The price we pay is a predisposition to cancer.
Stem cells with signiﬁcant DNA damage and, therefore,
malignant potential are marked for senescence or apoptosis.
While removing these cells is vital for maintaining genetic
integrity, it leaves an important niche unoccupied. Elegant
work from Ruzankina et al. [52] demonstrates that removing
these cells leads to a compensatory reaction of the remain-
ing stem cells. Using a novel mouse model, they were able
to show that removal of the majority of stem cells within
the gastrointestinal tract initially resulted in severe atrophy
of the intestinal tract, because of the loss of stem cells and
TA cells which repopulate this rapidly renewing epithelium.
After several weeks, however, the mice regained normal
intestinal histology with the formerly atrophic epithelium
repopulated by the surviving stem cells. These data show the
resilience of stem cells which are able to divide symmetri-
cally, expand the stem cell pool, and apparently migrate to
populate adjacent areas within the epithelium and to recon-
stitute dwindling stem cell pools which have been injured or
removed. The authors assume that the stem cell pools have
been repopulated by local cells; however, they did not
address the notion of recruitment of circulating stem cells to
participate in this repair. Despite this rapid and resourceful
use of stem cell plasticity, there appears to be a price to
pay. After a period of seemingly normal growth, the mice
rapidly aged, with greying of the fur, osteopenia and a decline
in haematopoietic function, suggesting that the forced repli-
cation of the remaining stem cells compromised their long-
term function and viability. If we use this animal model as an
example of what happens with forced stem cell replication
during the constant repair and restitution seen during
chronic inﬂammation, as in Helicobacter infection, we can
see how the constant push to replicate in order to repair
damaged epithelium may deplete stem cell function and stem
cell pools. Initially, recruited stem cells can take over this
function; however, as inﬂammation progresses, this compen-
satory function may be overwhelmed and the stem cell com-
partment unable to continue multi-lineage differentiation.
This loss of function and number likely underlies the atrophy
of tissue so commonly seen with longstanding inﬂammation.
This puts the peripheral tissue at risk of inadequate healing,
and also may set the stage for recruitment of more pluripo-
tent stem cells (i.e. from the bone marrow) to repopulate
the ‘empty niche’ [53]. Stem cells native to the tissue, or
recruited to the niche to replace dead or damaged stem
cells, are subjected to the inﬂammatory environment and the
cycle perpetuates itself.
Overall, the progression of several types of cancer, includ-
ing gastric cancer, is determined by the severity of the
inﬂammatory response which is regulated by NF-jB. Many of
the key pro-inﬂammatory cytokines, such as IL-6, IL-8, IL-1b
and TNF-a, are encoded by target genes of the IKKb-depen-
dent NF-jB activation pathway.
The in vivo importance of macrophage-derived NF-jB
expression has been demonstrated [54]. Using an ulcerative
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colitis model of colorectal cancer, Karin’s group showed that
disruption of the NF-jB pathway in myeloid cells resulted in
a marked reduction in expression of IL-1b, IL-6 and MIP-2
and a signiﬁcant reduction in colon cancer. In a similar man-
ner, deletion of IKKb in myeloid cells also decreases hepato-
cellular carcinoma in the mouse [55].
Proinﬂammatory factors act alone and in concert to create
an environment conducive to perpetuating inﬂammation and
creating a proneoplastic niche. Two factors, TNF-a and IL-1b,
have gained prominent attention. TNF is a major mediator of
inﬂammation, stimulating both tissue destruction and repair.
Via apoptotic signalling, injured cells are removed from areas
of damage while the same cytokine signalling stimulates ﬁbro-
blast growth geared towards tissue remodelling. There is evi-
dence that, while terminally differentiated cells undergo
apoptosis through TNF signalling, TNF may protect some
stem cell populations from apoptosis [56]. Paradoxically, mes-
enchymal stem cells are directly stimulated by TNF to produce
factors responsible for healing and neovascularization such as
VEGF, FGF2, HGF and IGF-1 by an NF-jB-dependent mecha-
nism [56]. Therefore, TNF both devastates and rebuilds blood
vessels via induction of angiogenic factors [58–60]. Newly
formed vessels are often unable to provide adequate oxygen
supplies to the tissue and a situation of relative hypoxia is per-
petuated. Once cancer arises in the setting of ongoing inﬂam-
mation, TNF appears to act directly on cancer cells to affect
the migration, adhesion and invasion of cells [61,62].
The second prominent player is IL-1b which is secreted
by macrophages, neutrophils and epithelial cells within the
chronic injured/inﬂamed tissue. IL-1b synergizes with TNF
for its multiple functions including its pro-inﬂammatory
effects and its effects on vascular permeability. As previously
outlined, polymorphisms within the IL-1b gene which are
associated with relatively higher tissue levels of IL-1b have
been linked to more severe inﬂammation and tissue damage
secondary to agents such as H. pylori, and are also linked to
a higher incidence of gastric cancer in infected patients
[12,45]. In a similar manner, Japanese patients with chronic
hepatitis C have a higher incidence of hepatocellular carci-
noma if they have a speciﬁc IL-1b polymorphism which con-
fers a greater proinﬂammatory proﬁle. IL-1b induces PGE2
production, hepatocyte growth factor and increased Th1
type cytokines, all of which are linked to a higher incidence
of hepatocyte transformation [46].
TNF-a and IL-1b, along with IL-6 and TGF-b, induce stro-
mal cells, tumour cells and resident stem cells to produce
VEGF. VEGF, a key angiogenic factor, induces neovasculariza-
tion into damaged and repairing tissues, which then alters tis-
sue oxygen tension, inducing relative hypoxia. Tissue hypoxia
in turn regulates survival programmes which may further
subvert growth of cells in favour of allowing genetically dam-
aged cells to survive [63]. Interestingly, oxygen concentra-
tions affect many aspects of stem cell physiology, and may be
a critical parameter during wound healing to promote expan-
sion and differentiation of stem cells. Studies support that
stem cell proliferation and differentiation of progeny con-
tinue in the presence of hypoxia long after normal con-
straints of contact inhibition and cell number would have
induced growth arrest [64].
What are the Long-Term Effects of
Chronic Inﬂammation?
If we look at the stomach as an example, Helicobacter infec-
tion causes a chronic gastritis which places the mucosa at
risk of developing gastric cancer. The sequence of events
and the histological alterations are well described in man and
in mouse models [65–68]. Chronic inﬂammation of the gas-
tric mucosa progresses through stages of hypertrophy, atro-
phy, metaplasia, dysplasia and ﬁnally adenocarcinoma. It is
not clear if one stage leads to the next; for example, is meta-
plasia a precursor lesion of dysplasia, and is dysplasia a pre-
cursor of adenocarcinoma? Conversely, these changes may
mark a ﬁeld of genetic alterations and signalling conducive to
cancer induction, but the cellular changes themselves may
not be directly premalignant [68].
If we look at the long-term consequences of chronic
inﬂammation at the cellular level, we see that chronic inﬂam-
mation dramatically alters the local cytokine network, inﬂu-
ences apoptotic and proliferative programmes, and directs
differentiation and remodelling with a profound impact on tis-
sue structure. This environment, directly and via impact on
cell–cell signaling, induces epigenetic changes and also directly
leads to heritable genetic changes of cells (Table 3). Atrophy
of the tissue is a common precursor of inﬂammatory-medi-
ated cancer in organs such as the stomach [69], pancreas [70]
and prostate [71]. Atrophy, which is the loss of the normal
TABLE 3. Cellular effects of chronic inﬂammation
Reactive oxygen species leading to DNA damage
No production leading to DNA mutations/alterations in DNA repair
Tissue hypoxia leading to alterations in gene regulation and angiogenesis
Inactivation of tumour suppressor genes
Up-regulation of anti-apoptotic genes
Induction of pro-proliferation programs
Activation of tumour promoters
Inactivation of tumour suppressors
Increased vascular permeability
Angiogenic factors leading to increased neovascularization
Tissue remodelling secondary to collagenases/MMPs
Alteration in cell–cell adhesion
Alterations in cell mobility
MMPs, matrix metalloproteinases.
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architecture and a drop-out of mature cell types, represents
the severe blow to the resident stem cells that inﬂammation
delivers. Further damage to the stem cell, manifesting as
abnormal differentiation, can be seen as metaplasia, i.e. the
replacement of one adult cell type with another. Metaplasia
can be the result of environmental inﬂuences on cellular dif-
ferentiation and may be reversible when the environment is
returned to its usual state. Often, however, metaplasia is
incomplete, with cells partially taking on characteristics of
another cell type, and these changes appear to be irreversible
despite removal of the stimulating environment.
This permanent change in tissue architecture and cellular
differentiation may represent permanent changes to the stem
cell. This evidence of a presumed pre-neoplastic permanent
change to the stem cell compartment further supports the
notion of the resident stem cell as the cancer stem cell, and
demonstrates the effect of the inﬂammatory environment on
this cell type.
Inﬂammation and Tumours: Inﬂammation’s
Many Roles
Once tumours develop, the role of inﬂammation continues.
Progression of cancer and metastasis can be viewed as similar
to the effects of inﬂammation on the premalignant tissue that
we have already described. Mesenchymal stem cells localize to
tumours as they form and progress, contributing to the local
growth of cells. Cells of bone marrow origin are recruited to
sites of inﬂammation and repair, and become home to areas
of malignancy. Studies addressing the role of bone marrow-
derived mesenchymal stem cells in breast cancer show that
these cells enhance the mobility and invasiveness of cancer
cells through production of RANTES (Regulated on Activa-
tion, Normal T Expressed and Secreted) [43]. The stromal
cells themselves are not malignant; however, they are inti-
mately involved in the signalling and fate of the cancer stem
cells through the local environment they create. This local
environment or niche is crucial for cancer cell growth, a point
which is poignantly obvious when one looks at sites of metas-
tasis. Elegant work from the laboratories of Raﬁi and Lyden
demonstrates that sites of metastatic tumours are set up
before the arrival of any tumour cells [44]. The details are still
being worked out; however, it appears that tumours arising in
different organs secrete a unique signature of factors which
act on peripheral tissues to orchestrate the pattern of metas-
tasis peculiar to each tumour type (e.g. melanoma metasta-
sizes widely; colon tumours metastasize to the liver; and
prostate cancer metastasizes preferentially to the bone).
These ﬁndings are contrary to the commonly held notion that
cancer cells gain access to the circulation and bully their way
into peripheral tissues to form metastatic disease. Indeed,
these new data suggest that circulating cancer cells are, in fact,
invited in. Factors such as vascular endothelial growth factor
(VEGF)-A, TGF-b and TNF-a produced by primary tumours
[72–74] act distally to activate local inﬂammatory and mesen-
chymal cells to up-regulate expression of the chemo-attrac-
tants S100A8 and S100A9. Coincident with this, bone
marrow-derived VEGFR1+ VLA4+ [44] or Mac1+ cells [74]
are recruited to set the stage for recruiting S100-responsive
tumour cells. While the precise details are still not clear, it
looks as if our understanding of and approach to metastatic
disease will be very different than it has been in the past.
Based on these new ﬁndings, metastasis can be viewed as an
active process whereby local tumour cells or tumour niche
cells elaborate factors which circulate and lead to changes in
peripheral organs. Environments conducive to growth of met-
astatic tumours are set up long before tumour cells arrive,
providing targets which may be exploited for anti-tumour
treatments.
CXCR4, a G-protein-coupled seven span trans-membrane
receptor, is expressed on the surface of many stem cells. The
ligand for CXCR-4 is the alpha-chemokine stromal-derived
factor (SDF-1). This ligand-receptor pair is unusual in that the
two members bind each other exclusively. CXCR4 is respon-
sible for regulating trafﬁcking of normal haematopoietic stem
cells and their mobilization and homing to the bone marrow
[75–77]. Furthermore, it is thought that CXCR4-SDF-1 is
used during embryogenesis for appropriate cell migration
[78]. It is well known that hematopoietic stem cells (HSC)
depend upon an SDF-1 gradient to home back to the marrow
cavity for circulation. Indeed, agents used to mobilize bone
marrow cells for transplant purposes propose do so by dis-
rupting the SDF-1/CXCR4 axis [79,80]. In a similar manner,
successful engraftment of the bone marrow transplant relies
heavily on an intact SDF-1/CXCR4-signalling axis. Inﬂamma-
tory tissues produce elevated levels of SDF-1, which act as
the lure for CXCR4-expressing marrow cells to home to
these sites [38].
Similar to their non-malignant stem cell counterparts,
many cancer cells express CXCR4. Like the haematopoietic
stem cells, it is believed that cancer stem cells use the
CXCR4 receptor to mobilize, invade and metastasize [80],
further supporting the notion that cancer stem cells derive
from a tissue stem cell source and utilize inﬂammatory envi-
ronments for growth and movement. If we look closely at
the function of the CXCR4 receptor zon normal or malig-
nant cells, we see that it is multi-factorial and modulated by
several components of the inﬂammatory environment. At
the molecular level, CXCR4 is regulated by factors related
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to stress and tissue damage, including NF-jB [82], HIF-1
[83], TGF-b [84], VEGF [85], IFN-a [86], IL-2, IL-4 and IL-7
[87,88], leading to increased surface expression. CXCR4 is
incorporated into lipid rafts with the protein Rac1 [89].
Statin drugs are associated with a decrease in malignancy
[90,91]. These seemingly peculiar clinical ﬁndings may be
explained by the effect of statin which is to inhibit intra-
cellular cholesterol synthesis, and hence, membrane choles-
terol levels. Factors that affect the cholesterol content of
the cell membrane may, therefore, signiﬁcantly affect the
response of the CXCR4 receptor to SDF-1. Also, proteases
may cleave SDF-1 to an inactive form and antagonize
CXCR4-SDF1 activities [92], and act to retain CXCR4-bear-
ing cells in tissues, functioning as a sponge. In addition to act-
ing as a chemotactic factor for CXCR4-bearing cells, SDF-1
has been shown to induce adhesion, and to induce secretion
of matrix metalloproteinases (MMPs) and VEGF in cells bear-
ing CXCR4 [93–96]. It can also increase interaction with
several integrins [95], thus impacting binding and migration.
SDF-1 may stimulate proliferation of several cell types,
including cancer cells [96]. Interestingly, SDF-1 levels are
highest in bone, lung, liver and lymph nodes, and may direct
metastasis of CXCR4-bearing cancer cells to these locations
[97–105] which are common sites of metastatic disease.
SDF-1 is increased in inﬂamed tissues and our own work has
shown elevated and sustained levels in the infected gastric
mucosa. This may in turn attract marrow-derived stem cells
to the area to participate in neo-vascularization, stroma
formation and engraftment into the stem cell niche for repair
[38].
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